A single intraperitoneal IOX2 dose of 37.7 mg/kg increased peripheral HIF1α/HIF2α signals in mice at 1 h, while brain induction was not detected under the same condition. [1]
In a mouse DMM osteoarthritis model, intra-articular IOX2 reduced cartilage damage and osteophyte scores and increased cartilage HIF1A, DOT1L and H3K79me2 staining. The synovial inflammation comparison did not reach statistical significance (P = 0.08). [2]
Acute tissue HIF response in mice
Animal study · Male C57BL/6 mice, 3 months old; liver, kidney, heart and brain [1]
IOX2 increased peripheral HIF1α/HIF2α signals, while brain induction was not detected under the tested condition. IOX4 produced brain induction in the comparator arm.
Conditions shared by the study groups
- Route
- Intraperitoneal
- Frequency
- Single injection
- Treatment course
- Tissues collected at 1 h
- Vehicle
- Hanks’ buffered saline, pH 7.0, with 5% DMSO final.
- IOX2 single-dose tissue comparison
- Model: Male C57BL/6 mice, 3 months old; liver, kidney, heart and brain
- Reported limits: Figure 4A biological n not stated in the read material; detection-limit result does not establish absence of brain penetration.
Methods and source locations
Compound reported in the paper: IOX2; Compound label in the paper: IOX2
Compound-level evidence only; no Adooq supplier, lot or formulation equivalence established.
Figure 4A and caption; Results: HIFα proteins are upregulated in tissues of mice treated with IOX4; Methods: Experiments in mice
HIF1α and HIF2α abundance across tissues: HIF1α/HIF2α immunoblots with β-actin loading control and vehicle, IOX4 and DMOG comparator lanes. — Figure 4A and caption; Results mouse comparison
IOX2 single-dose tissue comparison · Figure 4A; Methods: Experiments in mice
Local IOX2 treatment in a mouse osteoarthritis model
Animal study · Male wild-type C57BL/6 mice; DMM at 8 weeks of age; sham-operated and DMM vehicle controls [2]
Repeated intra-articular IOX2 reduced cartilage damage and osteophyte scores after DMM. Synovial inflammation did not reach statistical significance. HIF1A, DOT1L and H3K79me2 staining increased relative to DMM vehicle.
Conditions shared by the study groups
- Route
- Intra-articular
- Frequency
- Every 10 days
- Treatment course
- 7 injections, beginning 1 week after DMM; endpoint 12 weeks after surgery.
- Vehicle
- 30% PEG400 in PBS
- DMM with IOX2
- Model: Male wild-type C57BL/6 mice; DMM at 8 weeks of age; sham-operated and DMM vehicle controls
- Reported limits: No inference of human efficacy; histology and immunostaining have different stated sample sizes.
Methods and source locations
Compound reported in the paper: IOX2; Compound label in the paper: IOX2
Compound-level evidence only; no Adooq supplier, lot or formulation equivalence established.
Figure 6A–G and caption; Results: Intra-articular treatment with IOX2; Methods: DMM mouse model, Intra-articular IOX2 injections, Histology, Immunohistochemistry, Statistics
Cartilage damage, osteophytes and synovial inflammation: OARSI and histological scores; n = 6 sham vehicle, n = 8 each DMM vehicle and DMM IOX2. Kruskal-Wallis followed by Holm-Bonferroni-corrected pairwise Wilcoxon tests in Methods. Effect-size CIs bootstrap-based. — Figure 6B–D and caption; corresponding Results; Methods: Statistics
Cartilage HIF1A, DOT1L and H3K79me2 immunostaining: n = 5 mice/group, average of 2 technical replicates/mouse; staining relative to sham vehicle; mean ± SEM. Caption: one-way ANOVA with Šidák correction for 3 tests. Retains authors’ metric terminology; no reinterpretation as absolute intensity units. — Results corresponding to Figure 6E–G; Figure 6 caption; Methods: Immunohistochemistry
DMM with IOX2 · Figure 6A–G; Methods: Intra-articular IOX2 injections